Acute demyelinating optic neuritis

References

• Beck RW. The Optic Neuritis Treatment Trial. Arch. Ophthalmol.106, 1051–1053 (1988).
   PubMedGoogle Scholar
• Optic Neuritis Study Group. The clinical profile of acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol.109, 1673–1678 (1991).
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MA et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N. Engl. J. Med.326, 581–588 (1992).
   PubMed Web of Science ®Google Scholar
• Liu GT. Visual loss. optic neuropathies. In: Neuro-Ophthalmology: Diagnosis and Management. Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, PA, USA 103–187 (2000).
   Google Scholar
• Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter. the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology54, 2039–2044 (2000).
   PubMed Web of Science ®Google Scholar
• Balcer LJ, Galetta SL. Optic neuritis. In: Conn’s current therapy. Rakel RE, Bope ET (Eds.), WB Saunders, PA, USA 187–190 (2004).
   Google Scholar
• Balcer LJ. Optic Neuritis. N. Engl. J. Med.354, 43–50 (2006).
   Google Scholar
• Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am. J. Ophthalmol.139, 1101–1108 (2005).
   PubMed Web of Science ®Google Scholar
• Atkins EJ, Biousse V, Newman NJ. The Natural History of Optic Neuritis. Rev. Neurol.l Dis.3, 45–56 (2006).
   PubMedGoogle Scholar
• Newman NJ, Biousse V. Hereditary optic neuropathies. Eye18, 114–160 (2004).
   Google Scholar
• Wakakura M, Minei-Higa R, Oono S et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Jpn J. Ophthalmol.43, 127–132 (1999).
   PubMed Web of Science ®Google Scholar
• Wakakura M, Mashimo K, Oono S et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Jpn J. Ophthalmol.43, 133–138 (1999).
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of MS. N. Engl. J. Med.329, 1764–1769 (1993).
   PubMed Web of Science ®Google Scholar
• Beck RW, Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis. a need to change treatment practices. Neurology42, 1133–1135 (1992).
   PubMed Web of Science ®Google Scholar
• Beck RW, Kupersmith MJ, Cleary PA et al. Fellow eye abnormalities in acute unilateral optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology100, 691–698 (1993).
   PubMed Web of Science ®Google Scholar
• Beck RW, Arrington J, Murtagh FR, et al. Brain MRI in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch. Neurol.8, 841–846 (1993).
   Google Scholar
• Optic Neuritis Study Group. The five-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology49, 1404–1413 (1997).
   PubMed Web of Science ®Google Scholar
• Keltner JL, Johnson CA, Spurr JO et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol.111, 231–234 (1993).
   PubMedGoogle Scholar
• Beck RW, Cleary PA, Backlund J et al. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology101, 1771–1178 (1994).
   PubMed Web of Science ®Google Scholar
• Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. Am. J. Ophthalmol.121, 547–553 (1996).
   PubMed Web of Science ®Google Scholar
• The Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch. Ophthalmol.115, 1545–1552 (1997).
   PubMedGoogle Scholar
• Keltner JL, Johnson CA, Spurr JO, Beck RW, for the Optic Neuritis Study Group. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. Am. J. Ophthalmol.128, 543–553 (1999).
   PubMed Web of Science ®Google Scholar
• Fang JP, Donahue SP, Lin RH. Global visual field involvement in acute unilateral optic neuritis. Am. J. Ophthalmol.128, 554–565 (1999).
   PubMedGoogle Scholar
• Fang JP, Lin RH, Donahue SP. Recovery of visual field function in the Optic Neuritis Treatment Trial. Am. J. Ophthalmol.128, 566–572 (1999).
   PubMedGoogle Scholar
• Arnold AC. Visual field defects in the Optic Neuritis Treatment Trial: central vs peripheral, focal vs global. Am. J. Ophthalmol.128, 632–634 (1999).
   PubMed Web of Science ®Google Scholar
• Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH, for the Optic Neuritis Study Group. Visual symptoms after optic neuritis: results from the Optic Neuritis Treatment Trial. J. Neuroophthalmol.17, 18–28 (1997).
   PubMed Web of Science ®Google Scholar
• Cole SR, Beck RW, Moke PS, Gal RL, Long DT, and the Optic Neuritis Study Group. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Invest. Ophthalmol. Vis. Sci.41, 1017–1021 (2000).
   PubMed Web of Science ®Google Scholar
• Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the Optic Neuritis Treatment Trial on the practices of ophthalmologists and neurologists. Ophthalmology106, 2047–2053 (1999).
   PubMed Web of Science ®Google Scholar
• Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development of MS within 10 years after optic neuritis. Arch. Ophthalmol.121, 944–949 (2003).
   PubMed Web of Science ®Google Scholar
• Beck RW, Optic Neuritis Study Group. The Optic Neuritis Treatment Trial: implications for clinical practice. Arch. Ophthalmol.110, 331–332 (1992).
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis. experience of the optic neuritis treatment trial. Am. J. Ophthalmol.137, 77–83 (2004).
   PubMed Web of Science ®Google Scholar
• de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br. J. Ophthalmol.90, 551–554 (2006).
   PubMed Web of Science ®Google Scholar
• Frisen L, Hoyt WF. Insidious atrophy of retinal nerve fibers in multiple sclerosis. funduscopic identification in patients with and without visual complaints. Arch. Ophthalmol.92, 91–7 (1974).
   PubMedGoogle Scholar
• Balcer LJ, Baier ML, Pelak VS et al. New low-contrast vision charts. reliability and test characteristics in patients with MS. Mult. Scler.6, 163–171 (2000).
   PubMed Web of Science ®Google Scholar
• Cole SR, Beck RW, Moke PS et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Neurology51, 885–887 (1998).
   PubMedGoogle Scholar
• Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N et al. Clinically isolated syndromes. A new oligoclonal band test accurately predicts conversion to MS. Neurology66, 576–578 (2006).
   PubMed Web of Science ®Google Scholar
• Balcer LJ. MS and related demyelinating diseases. In: Walsh & Hoyt’s Clinical Neuro-ophthalmology, Vol. 3, 6th Edition. Miller NR, Newman NJ, Biousse V, Kerrison JB (Eds), Lippincott, Williams & Wilkins, PA, USA 3429–3525 (2005).
   Google Scholar
• Fraser CL, Klistorner A, Graham SL, Garrick R, Billson FA, Grigg JR. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology113, 315–323 (2006).
   Google Scholar
• Polman CH, Reingold SC, Edan G et al. Diagnostic Criteria for MS. 2005 Revisions to the McDonald Criteria. Ann. Neurol.58, 840–846 (2005).
   PubMed Web of Science ®Google Scholar
• Fraser C, Klistorner A, Graham S, Garrick R, Billson F, Grigg J. Multifocal visual evoked potential latency analysis. predicting progression to multiple sclerosis. Arch. Neurol.63, 847–850 (2006).
   PubMedGoogle Scholar
• Trip SA, Wheeler-Kingshott C, Jones SJ et al. Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage30, 498–505 (2006).
   PubMedGoogle Scholar
• Hickman SJ, Wheeler-Kingshott CA, Jones SJ et al. Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. Am. J. Neuroradiol.26, 951–956 (2005).
   PubMed Web of Science ®Google Scholar
• Frohman EM, Frohman TC, Zee DS et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol.4, 111–121 (2005).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM et al. Axonal transaction in the lesions of multiple sclerosis. N Engl J338, 278–285 (1998).
   Google Scholar
• Costello F, Coupland S, Hodge W et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann. Neurol.59, 963–969 (2006).
   PubMed Web of Science ®Google Scholar
• Sergott RP, Piette S, Etter J, Savino P. In vivo neuroprotection with high-dose, high-frequency interferon therapy. A serial optical coherence tomography study in multiple sclerosis and optic neuritis. Proceedings of the 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. Thessaloniki, Greece, September 28–October 1 2005.
   Google Scholar
• Trip SA, Schlottmann PG, Jones SJ et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann. Neurol.58, 383–391 (2005).
   PubMed Web of Science ®Google Scholar
• Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in MS. Ophthalmology113, 324–332 (2006).
   PubMed Web of Science ®Google Scholar
• Rebolleda G, Munoz-Negrete FJ, Noval S, Contreras I, Gilbert ME, Sergott RC. New ways to look at an old problem. Surv. Ophthalmol.51, 169–173 (2006).
   PubMedGoogle Scholar
• Drug Topics Red Book. Thomson PDR, Montvale, NJ, USA (2005).
   Google Scholar
• Jacobs LD, Cookfair D, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing MS. Ann. Neurol.39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β -1a therapy initiated during a first demyelinating event in MS. N. Engl. J. Med.343, 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• CHAMPS Study Group. Interferon β-1a for optic neuritis patients at high risk for MS. Am. J. Ophthalmol.132, 463–471 (2001).
   PubMed Web of Science ®Google Scholar
• Kinkel RP, Kollman C, O’Connor P et al. IM Interferon β-1a delays definite MS 5 years after a first demyelinating event. Neurology66, 678–684 (2006).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite MS. a randomized study. Lancet357, 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Inglese M et al. Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis. A randomised, double-blind, placebo-controlled trial. Lancet364, 1489–96 (2004).
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS et al. Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology67, 1242–1249 (2006).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Weinshenker BG, Noseworthy JH et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol.63, 611–614 (2006).
   PubMedGoogle Scholar
• Frohman EM, Havrdova E, Lublin F et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol.63, 614–619 (2006).
   PubMedGoogle Scholar
• Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis. Neurology63, 1081–1083 (2004).
   PubMed Web of Science ®Google Scholar
• Van Engelen BGM, Hommes OR, Pinkers A et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis (letter). Ann. Neurol.32, 834–835 (1992).
   PubMedGoogle Scholar
• Roed HG, Langkilde A, Sellebjerg F et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology64, 804–810 (2005).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, O’Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology56, 1514–1522 (2001).
   PubMed Web of Science ®Google Scholar
• Achiron A, Kishner I, Sarova-Pinhas I et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. Arch. Neurol.61, 1515–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Brady KM, Brar AS, Lee AG et al. Optic neuritis in children: clinical features and visual outcome. J. AAPOS3, 98–103 (1999).
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Kiers L, O’Duffy A et al. Risk factors for developing MS after childhood optic neuritis. Neurology49, 1413–1418, 1997.
   PubMed Web of Science ®Google Scholar
• Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology67, 258–262 (2006).
   PubMedGoogle Scholar
• Galetta SL, Bennett J. Neuromyelitis Optica is a variant of multiple sclerosis. Arch. Neurol. (In press).
   Google Scholar
• Filippi M, Rocca MA. MR imaging of Devic’s neuromyelitis optica. Neurol. Sci.25, 371–373 (2004).
   Google Scholar
• Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch. Neurol.63, 390–396 (2006).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuck DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica. distinction from multiple sclerosis. Lancet364, 2106–2112 (2005).
   Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology66, 1485–1489 (2006).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med202, 473–477 (2005).
   Google Scholar
• Mandel RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica. a prospective study of seven patients treated with prednisone and azathioprine. Neurology51, 1219–1220 (1998).
   PubMedGoogle Scholar
• Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology64, 1270–1272 (2005).
   PubMed Web of Science ®Google Scholar
• Brex PA, Miszkiel KA, O’Riordan JI et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes. the role of follow-up MRI. J. Neurol. Neurosurg. Psychiatry70, 390–393 (2001).
   PubMedGoogle Scholar
• Schmalfuss IM, Dean CW, Sistrom C, Bhatti MT. Optic neuropathy secondary to cat scratch disease: distinguishing MR imaging features from other types of optic neuropathies. Am. J. Neuroradiol.26, 1310–1316 (2005).
   PubMed Web of Science ®Google Scholar
• Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA273, 625–632 (1995).
   PubMed Web of Science ®Google Scholar